Physitrack Reports 14% Q3 Revenue Growth as US Expansion Drives Strong Demand
Physitrack Plc (PTRK) posted a 14 per cent year-on-year increase in revenue for the third quarter of 2026, reaching EUR 3.6 million. The digital health company benefited from higher subscription pricing and expanding demand for its core software platform, marking its strongest growth quarter of the year. Shares traded up 10.00 per cent following the announcement.
Despite top-line gains, adjusted EBITDA fell 8 per cent to EUR 1.1 million as Physitrack invested heavily in its North American sales team and launched several new features, including a new Electronic Medical Record product and Remote Therapeutic Monitoring tools. Operating cash flow remained positive at EUR 1.1 million for the eighth straight quarter. Commercially, the company secured selections from two major US healthcare systems, reinforcing its expansion into the North American market.
Looking ahead, Physitrack is focused on commercialising its newly launched tools, finalizing terms with its new US health system partners, and converting early access users into paid subscribers starting January 2027. Management also aims to rebuild enterprise recurring revenue in its Wellness division while maintaining capital discipline and reducing net debt.
Key points
- Revenue rose 14% year-on-year to EUR 3.6 million in Q3 2026, led by strong software subscription growth.
- Adjusted EBITDA decreased 8% to EUR 1.1 million due to planned spending on North American sales and product launches.
- Operating cash flow reached EUR 1.1 million, representing the company's eighth consecutive quarter of positive cash generation.
- Selected by two US healthcare systems during the quarter, including integration with major clinical software platforms.
Written by our AI from expert market sources across the web. It can contain mistakes: check the facts before acting on them. Write-ups powered by the free AI API at FreeTheAI.org
How we writeDisclaimerQuestions and answers
How did Physitrack perform in Q3 2026?
Physitrack revenue grew 14 per cent year-on-year to EUR 3.6 million, supported by subscription software demand. Adjusted EBITDA fell 8 per cent to EUR 1.1 million due to growth investments in North America.
Why did Physitrack EBITDA decline in Q3?
Adjusted EBITDA dropped 8 per cent to EUR 1.1 million as Physitrack increased investment in its North American commercial team and rolled out three product launches during the quarter.
What new contract deals did Physitrack secure?
Physitrack was selected by two US healthcare systems in Q3, including an academic healthcare system and a metropolitan safety-net system integrated with Epic and MyChart.